Apollomics Inc. is a biotechnology company focused on developing innovative oncology therapies for challenging cancers like lung and brain cancer. APL-101 (vebreltinib) is a targeted therapy with positive results from clinical trials involving over 280 patients. Despite initially planning to discontinue clinical trials due to financial concerns, Apollomics received $4.1 million in funding and appointed a new leadership team. The company is now committed to continuing the global Phase 2 trial of APL-101 and strengthening its clinical development programs. Apollomics also plans to leverage approvals in China to pursue regulatory submissions in other markets. SEC filings for Apollomics are now publicly available on the SEC’s website. The company will not update forward-looking statements unless required by law.

Read more at 1. “Tech giant Apple announces record-breaking quarterly revenue of $111.4 billion, driven by strong iPhone sales and growth in services. The company’s stock price surges 3% in after-hours trading.” – Bloomberg

2. “Amazon reports a 42% increase in fourth-quarter revenue, reaching $125.6 billion, surpassing analyst expectations. The e-commerce giant also announces plans to hire 75,000 new employees in fulfillment and transportation roles.” – CNBC

3. “Tesla’s stock price jumps 5% after the electric vehicle maker posts its first full-year profit, exceeding $721 million in net income. Tesla also announces plans to expand production capacity in China and build a new factory in Texas.” – Reuters

4. “Facebook announces a 33% increase in fourth-quarter revenue, totaling $28.1 billion, driven by strong advertising demand. The social media company’s daily active users reach 1.84 billion, a 11% year-over-year increase.” – Wall Street Journal

5. “Google’s parent company Alphabet reports a 23% increase in fourth-quarter revenue, reaching $56.9 billion, fueled by growth in advertising and cloud services. The tech giant’s profit jumps to $15.2 billion, exceeding analyst expectations.” – CBS MarketWatch: Apollomics, Inc. Company Operational Continuity Update